CN102883738A - 治疗血管发生相关的眼部疾病的组合物和方法 - Google Patents

治疗血管发生相关的眼部疾病的组合物和方法 Download PDF

Info

Publication number
CN102883738A
CN102883738A CN2010800594090A CN201080059409A CN102883738A CN 102883738 A CN102883738 A CN 102883738A CN 2010800594090 A CN2010800594090 A CN 2010800594090A CN 201080059409 A CN201080059409 A CN 201080059409A CN 102883738 A CN102883738 A CN 102883738A
Authority
CN
China
Prior art keywords
malaysia
protein variant
compositions
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800594090A
Other languages
English (en)
Chinese (zh)
Inventor
庄韦杰
傅文美
黄彦伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cheng Kung University
Original Assignee
National Cheng Kung University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cheng Kung University filed Critical National Cheng Kung University
Publication of CN102883738A publication Critical patent/CN102883738A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2010800594090A 2009-12-23 2010-12-22 治疗血管发生相关的眼部疾病的组合物和方法 Pending CN102883738A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28962409P 2009-12-23 2009-12-23
US61/289,624 2009-12-23
PCT/US2010/061738 WO2011079175A1 (en) 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases

Publications (1)

Publication Number Publication Date
CN102883738A true CN102883738A (zh) 2013-01-16

Family

ID=44151942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800594090A Pending CN102883738A (zh) 2009-12-23 2010-12-22 治疗血管发生相关的眼部疾病的组合物和方法

Country Status (14)

Country Link
US (1) US9044436B2 (cg-RX-API-DMAC7.html)
EP (1) EP2515926A4 (cg-RX-API-DMAC7.html)
JP (1) JP5739908B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120130752A (cg-RX-API-DMAC7.html)
CN (1) CN102883738A (cg-RX-API-DMAC7.html)
AR (1) AR079706A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010336475A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012015188A8 (cg-RX-API-DMAC7.html)
CA (1) CA2782796A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007416A (cg-RX-API-DMAC7.html)
NZ (1) NZ600544A (cg-RX-API-DMAC7.html)
RU (1) RU2012131251A (cg-RX-API-DMAC7.html)
TW (1) TWI581801B (cg-RX-API-DMAC7.html)
WO (1) WO2011079175A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108430489A (zh) * 2015-06-28 2018-08-21 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
US12304037B2 (en) 2021-11-03 2025-05-20 Aob Products Company Torque driver

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2015147616A1 (ko) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
CA2958906C (en) * 2014-08-22 2021-05-04 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
WO2016108669A1 (ko) 2014-12-31 2016-07-07 주식회사 휴온스 Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR20250021281A (ko) 2023-08-04 2025-02-12 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물
WO2025033777A1 (ko) 2023-08-04 2025-02-13 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
WO2008088548A2 (en) * 2006-12-26 2008-07-24 National Taiwan University Disintegrin variants and pharmaceutical uses thereof
CN102470156A (zh) * 2009-07-20 2012-05-23 成功大学 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6710030B1 (en) * 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
WO2003042354A2 (en) * 2001-09-04 2003-05-22 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
JP2005529166A (ja) 2002-06-07 2005-09-29 ウィスコンシン アルムニ リサーチ ファウンデーション ペプチドカップリングのための試薬の化学合成
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
WO2008088548A2 (en) * 2006-12-26 2008-07-24 National Taiwan University Disintegrin variants and pharmaceutical uses thereof
CN102470156A (zh) * 2009-07-20 2012-05-23 成功大学 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108430489A (zh) * 2015-06-28 2018-08-21 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
CN108430489B (zh) * 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
US12304037B2 (en) 2021-11-03 2025-05-20 Aob Products Company Torque driver
US12447591B1 (en) 2021-11-03 2025-10-21 Aob Products Company Torque driver

Also Published As

Publication number Publication date
US20110152192A1 (en) 2011-06-23
RU2012131251A (ru) 2014-01-27
JP2013515739A (ja) 2013-05-09
EP2515926A4 (en) 2013-10-09
BR112012015188A8 (pt) 2016-08-09
TW201138801A (en) 2011-11-16
BR112012015188A2 (pt) 2016-04-05
WO2011079175A1 (en) 2011-06-30
US9044436B2 (en) 2015-06-02
KR20120130752A (ko) 2012-12-03
TWI581801B (zh) 2017-05-11
MX2012007416A (es) 2012-07-23
AU2010336475A1 (en) 2012-06-14
NZ600544A (en) 2014-06-27
CA2782796A1 (en) 2011-06-30
AR079706A1 (es) 2012-02-15
JP5739908B2 (ja) 2015-06-24
EP2515926A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
JP5739908B2 (ja) 血管形成関連の眼疾患の処置のための組成物および方法
Joseph et al. Recent perspectives on the delivery of biologics to back of the eye
ES2960598T3 (es) Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
RU2680096C2 (ru) Липосомальные препараты
CA2718161C (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
JP2024016207A (ja) 滲出型加齢性黄斑変性の治療のための組成物
JP5954736B2 (ja) 難治性炎症性腸疾患の予防又は治療方法
JP6266811B2 (ja) 血管新生病の免疫療法
JP5934229B2 (ja) 眼血管疾患の処置のための投与計画
CN109384830B (zh) 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
US20190388522A1 (en) Methods for treating disorders associated with angiogenesis and neovascularization
JP2013049701A (ja) 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
MX2012000895A (es) Polipeptidos selectivos para integrina alfavbeta3 conjugada con una variante de albumina de suero humana (hsa) y usos farmaceuticos de los mismos.
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
JPWO2012105610A1 (ja) 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US11369575B2 (en) PPARα agonist compositions and methods of use
KR101467841B1 (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
TWI791440B (zh) Dsg2-衍生肽
RU2817350C2 (ru) Липосомальные препараты
CA3235772A1 (en) Encapsulated cells expressing il-2 and uses thereof
JP2025517038A (ja) 黄斑浮腫又は網膜静脈閉塞の治療における使用のための単量体アネキシンa5
CA3253955A1 (en) ANNEXIN A5 MONOMER FOR USE IN THE TREATMENT OF MACULAR EDEMA OR RETINAL VEIN OCCUSION
Schiffelers et al. Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals
WO2020120480A1 (en) Vasodilators for use in the treatment of a retinal ischemic disorder

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130116